Covaxin has 100% efficacy against severe COVID-19 disease: Phase 3 interim analysis |
News and Updates
eMediNexus Coverage from: 
Covaxin has 100% efficacy against severe COVID-19 disease: Phase 3 interim analysis

2 Read Comments                

Bharat Biotech has announced second interim results from Phase 3 trials. The company and ICMR stated that Covaxin showed 78% vaccine efficacy against COVID-19 disease and 100% efficacy against severe disease with an effect on reduction in hospitalizations. The efficacy against asymptomatic COVID-19 infection was 70%, pointing to diminished transmission in recipients of the vaccine.

The Phase 3 study had recruited 25,800 participants aged 18-98 years, including 10% above the age of 60, and the analysis was conducted 14 days after the second dose. The company revealed that the safety and efficacy results from the final analysis will be available in the month of June, and the final report will be submitted to a peer-reviewed publication… (ET Healthworld, April 21, 2021)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now